Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1: GU tumours, non-prostate

513MO - Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders


11 Sep 2022


Mini Oral session 1: GU tumours, non-prostate


Tumour Site

Malignant Germ-Cell Tumours of the Adult Male


Anna Jansson


Annals of Oncology (2022) 33 (suppl_7): S233-S234. 10.1016/annonc/annonc1053


A.K. Jansson1, J. Söderling2, J. Reutfors2, A. Thor3, C. Sköld1, G. Cohn-Cedermark4, O. Ståhl5, K. Ekström Smedby2, A. Pettersson2, I. Glimelius1

Author affiliations

  • 1 Department Of Immunology, Genetics And Pathology, University Hospital Uppsala/Akademiska Sjukhuset, 751 85 - Uppsala/SE
  • 2 Department Of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, 171 77 - Stockholm/SE
  • 3 Department Of Clinical Science, Intervention And Technology, Division Of Urology, Karolinska Institutet, 141 83 - Huddinge/SE
  • 4 Department Of Oncology-pathology, Department Of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska Institutet, 171 77 - Stockholm/SE
  • 5 Department Of Oncology, Skåne University Hospital, 222 41 - Lund/SE


Login to access the resources on OncologyPRO.

Abstract 513MO


Clinical observations indicate a higher prevalence of psychiatric disorders, in particular neurodevelopmental disorders, among testicular germ cell cancer (TGCC) patients. Our aim was to investigate if history of specific psychiatric disorders is associated with increased risk of TGCC and/or increased mortality.


We conducted a nested case-control study including 6,250 TGCC patients diagnosed 1992-2014, individually matched to 62,500 controls. Using conditional logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) for the association between history of psychiatric diagnoses and TGCC risk. Among the cases only, we used a cohort study design and Cox regression to calculate hazard ratios (HRs) with 95% CIs of the association between psychiatric diagnosis and all-cause and TGCC-specific mortality.


History of a neurodevelopmental disorder (i.e., attention deficit hyperactivity disorder, autism spectrum disorder and intellectual disabilities) was associated with an increased risk of seminoma (OR 1.54; 95% CI 1.09-2.19). Seminoma patients with neurodevelopmental disorders were also younger (34 versus 38 years, p=0.004) and more often presented with stage IV disease (5.4% versus 1.2%) than those without. A decreased risk of seminoma was seen for patients with psychotic disorders (OR 0.62; 95% CI 0.40-0.96). Psychiatric history overall was not associated with TGCC. Patient history of any psychiatric disorder was associated with an increased all-cause mortality (HR 2.91; 95% CI 2.11-4.02) and an increased TGCC-specific mortality (HR 1.79; 95% CI 1.04-3.08).


We report, for the first time, an association between neurodevelopmental disorders and testicular seminoma. Furthermore, we found an increased TGCC-specific mortality for TGCC-patients with psychiatric disorders.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Uppsala University, Research group Ingrid Glimelius.


Swedish Cancer Society (CAN 19 0123 Pj).


A. Pettersson: Financial Interests, Personal, Other, Honoraria: Capio St. Göran; Financial Interests, Personal, Other, Honararia: Astellas Pharma; Financial Interests, Personal, Other, Honoraria: Mediahuset i Göteborg; Financial Interests, Personal, Other, Advisor: Janssen-Cilag; Financial Interests, Personal, Other, Grants: Merck & Co.; Financial Interests, Personal, Other, CEO and Co-Founder: Levo Prevention AB. I. Glimelius: Financial Interests, Institutional, Other, I participate as Scientific Board on an Educational Event: Janssen-Cilag; Financial Interests, Personal, Other, I participate in a Real-World Initiative to Study Register-Based Data Supported by: Takeda; Financial Interests, Personal, Other, Safety Board for Evaluation of Side-Effects from the Viral Vector Developed within the Company: Lokon Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.